Statute Details
- Title: Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013
- Act Code: MA1975-S38-2013
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), section 77
- Enacting Formula: Made by the Minister for Health under section 77 of the Medicines Act
- Citation: “Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013”
- Commencement: Deemed to have come into operation on 3 October 2011
- Key Provisions:
- Section 1: Citation and commencement
- Section 2: Definition of “cosmetic product” by reference to the Health Products Act
- Section 3: Cessation of application of the Medicines Act to cosmetic products
- Related Legislation: Health Products Act (Cap. 122D); Medicines Act (Cap. 176)
- Status (as provided): Current version as at 27 Mar 2026
What Is This Legislation About?
The Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 is a short but legally significant instrument. In essence, it removes “cosmetic products” from the regulatory reach of the Medicines Act by providing that the provisions of the Medicines Act cease to apply to such products from a specified date.
Although the Order is dated 2013, it is expressly deemed to have come into operation on 3 October 2011. This means that, for legal purposes, the change in regulatory treatment took effect from that earlier date, not from the date the Order was made. Practitioners should therefore treat the cessation as having applied since 3 October 2011.
The Order also clarifies what counts as a “cosmetic product” by tying the definition to the First Schedule to the Health Products Act. This cross-reference is crucial: it ensures that the classification of cosmetic products is consistent with the Health Products regulatory framework, rather than being determined ad hoc under the Medicines Act.
What Are the Key Provisions?
Section 1 (Citation and commencement) provides the formal name of the Order and its effective date. The Order may be cited as the “Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013”. The operative legal point is the commencement clause: the Order is “deemed to have come into operation on 3rd October 2011”.
For lawyers advising regulated entities, this deemed commencement can affect compliance timelines, licensing/registration status, and potential regulatory exposure for conduct occurring between 3 October 2011 and the date the Order was made. Even though the Order was made on 24 January 2013, the legal effect is anchored to 3 October 2011.
Section 2 (Definition) defines “cosmetic product” by reference to the First Schedule to the Health Products Act (Cap. 122D). In practical terms, this means that the scope of the Order depends on the Health Products Act’s scheduled categorisation. If the First Schedule is amended in the future, the meaning of “cosmetic product” for the purposes of this Order may shift accordingly (subject to how amendments are drafted and any transitional provisions in the amending legislation).
Section 3 (Cessation of application of Act) is the operative provision. It states that “the provisions of the Act shall cease to apply to any cosmetic product as from 3rd October 2011.” The “Act” in this context refers to the Medicines Act (Cap. 176), as indicated by the authorising provision and the title of the Order.
In plain language, Section 3 draws a regulatory boundary: once the cessation takes effect, cosmetic products are no longer regulated under the Medicines Act’s regime. Instead, they fall to be regulated under the appropriate framework—most notably the Health Products Act, which is designed to govern health products including cosmetic products as classified in its First Schedule.
From a compliance perspective, this cessation can have multiple downstream effects. For example, obligations that would otherwise arise under the Medicines Act—such as requirements relating to licensing, product registration, manufacturing controls, import controls, labelling/advertising restrictions, or enforcement mechanisms—would no longer apply to cosmetic products as such. However, this does not mean cosmetic products are unregulated; rather, they are regulated under a different statutory scheme.
How Is This Legislation Structured?
The Order is structured in a simple, three-part format:
(1) Section 1: Citation and commencement. This section establishes the legal identity of the instrument and its effective date.
(2) Section 2: Definition. This section prevents ambiguity by defining “cosmetic product” through a cross-reference to the Health Products Act’s First Schedule.
(3) Section 3: Cessation of application. This is the core legal mechanism that terminates the Medicines Act’s applicability to cosmetic products from the specified date.
Notably, the Order contains no detailed procedural provisions, transitional arrangements, or enforcement clauses. Its function is purely to reallocate regulatory coverage by stopping the Medicines Act from applying to a defined category of products.
Who Does This Legislation Apply To?
This Order applies to cosmetic products as defined by the Health Products Act’s First Schedule. The legal effect is therefore directed at the regulatory status of those products, rather than at particular persons by name.
In practice, the Order will be relevant to businesses and professionals involved in the lifecycle of cosmetic products—such as manufacturers, importers, distributors, retailers, and compliance officers—because their regulatory obligations will depend on which statute governs the product category. If a product is properly characterised as a “cosmetic product” under the Health Products Act schedule, it will fall outside the Medicines Act regime from 3 October 2011.
Lawyers should also consider the classification risk: if a product is borderline between a cosmetic product and a medicine (or another regulated category), the cessation of Medicines Act coverage for cosmetic products may not resolve the question. Instead, it may shift the analysis to the correct classification under the Health Products Act and related regulatory instruments.
Why Is This Legislation Important?
Although the Order is brief, it is important because it clarifies and formalises a regulatory boundary between the Medicines Act and the Health Products Act. Such boundary-setting instruments are often critical in Singapore’s regulatory landscape, where product classification determines which licensing, compliance, and enforcement regime applies.
For practitioners, the most practical significance lies in the deemed commencement date and the cross-referenced definition. The deemed commencement means that compliance assessments for conduct from 3 October 2011 onward should be made on the assumption that cosmetic products were no longer governed by the Medicines Act. The cross-reference means that classification should be checked against the Health Products Act’s First Schedule rather than relying solely on marketing descriptions or internal product labels.
From an enforcement and risk management perspective, the cessation can affect how regulators approach investigations and compliance actions. If a product is a cosmetic product, enforcement that relies on Medicines Act provisions would be legally misdirected after the cessation date. Conversely, regulated entities should ensure that they comply with the correct obligations under the Health Products framework, including any requirements relating to product notification/registration (where applicable), labelling, advertising, and quality/safety controls.
Finally, this Order illustrates a common legislative technique: using subsidiary legislation to adjust the scope of a principal Act without amending the principal Act itself. This can make the regulatory system more adaptable, but it also requires practitioners to read across instruments and understand how definitions and schedules interact.
Related Legislation
- Medicines Act (Cap. 176)
- Health Products Act (Cap. 122D) (including the First Schedule)
Source Documents
This article provides an overview of the Medicines (Cessation of Application of Act to Cosmetic Products) Order 2013 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.